Back

Innovative strategies for lipid lowering treatment: PCSK9 inhibition

26 August 2018 (08:30 - 08:52)
Organised by:
Congress Presentation Part of: Innovative strategies for secondary prevention Treatment ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Francois Mach

University hospitals of Geneva, Geneva (Switzerland)

3 More presentations in this session

Presentation thumbnail
Anti-inflammatory therapy : interleukin-1 beta inhibition to prevent cardiovascular events
Doctor P. Ridker (Boston, US)
Slides Video
Presentation thumbnail
Prolonged P2Y12 inhibition or Factor Xa inhibition in patients after an acute coronary syndrome
Doctor T. Cuisset (Marseille, FR)
Slides Video
Presentation thumbnail
Balancing residual inflammatory, lipid, and thrombotic risk in coronary artery disease
Professor P. Libby (Boston, US)
Slides Video

Access the full session

Session thumbnail
Innovative strategies for secondary prevention

The Event

Event poster

ESC Congress 2018

26 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Targeting the PCSK9 pathway: where do novel therapies fit in?
26 August 2022
thumbnail
Congress Presentation
Effect and safety of PCSK9 inhibitor in-hospital use on blood lipid level in the ACS patients: a systematic review and meta-analysis
13 April 2024
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021
thumbnail
Congress Presentation
Time course of LDL-C lowering after initiation of PCSK9 inhibition or bempedoic acid in atherosclerotic cardiovascular disease
20 March 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources